Unit:
Marine Industry Department of Investment Promotion Committee, Pingtan Comprehensive Experimental Zone
Project Area:
pingtan Marine Life High-tech Industrial Base
Industry:
Biological and New Pharmaceutical Industry
Type of Project:
New Project
Cooperation Mode:
Collaborate
Nature of Project:
Encourage
Working Progress in Prior Period:
none
Total Investment:
discussed in detai
Expected to Attract Investment:
discussed in detai
Benefit Analysis:
none
Reason and Condition:
none
Content and Scale:
The project plans to cover an area of 13.33 hectares and build a production workshop of 160,000 square meters following GMP standards. An internationally cutting-edge R&D and innovation center will be established to conduct in-depth research on the application of stem cells in cosmetics. There'll also be an automated unclosed finished product warehouse to solve the problem of efficient storage and logistics of finished products, and a world-class raw material production workshop to realize full automation of production and packaging.
Others:
none
Industry

Biomedicine

In 2025, Fujian Province had 341 above-designated-size pharmaceutical enterprises, achieving an operating revenue of RMB 50.28 billion. The province's pharmaceutical industry has cultivated a relatively comprehensive industrial system covering categories such as chemical APIs (active pharmaceutical ingredients), chemical drug preparations, biopharmaceuticals, traditional Chinese medicine (TCM) prepared prescriptions, TCM decoction pieces, and medical devices. During the "14th Five-Year Plan" period, 4 Category-1 innovative drugs and 4 Category-2 innovative drugs were approved, accelerating industrial innovation. Maxim Biotech and Double Medical were promoted as leaders in the industrial chain. 6 projects from 3 enterprises, including Double Medical, were shortlisted for the Ministry of Industry and Information Technology's List of “Open Bidding for Selecting the Best Candidates for Innovation Tasks in Biomedical Materials.” 11 provincial-level industrial leading enterprises in biomedicine, such as Zhangzhou Pien Tze Huang Pharmaceuticals, and 17 enterprises under cultivation for leading status were fostered. 3 enterprises, including AmoyDx, were recognized as national single-item champions (in specific products); 25 enterprises, including Fukang Pharmaceuticals, were recognized as provincial single-item champions (in specific products). 19 pharmaceutical enterprises, including Southern Pharmaceuticals and Fukang Pharmaceuticals, were recognized as National "Little Giants" Enterprises Using Specialized and Advanced Technologies to Create Innovative and Unique Products. 15 enterprises, including Double Medical, Cosunter Pharmaceutical, and Haixi Pharmaceuticals, are listed companies.